HAEGTFTSD

CAS No. 926018-45-3

HAEGTFTSD( —— )

Catalog No. M30151 CAS No. 926018-45-3

HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 374 Get Quote
10MG 598 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    HAEGTFTSD
  • Note
    Research use only, not for human use.
  • Brief Description
    HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.
  • Description
    HAEGTFTSD is the first N-terminal 1-9 residues of GLP-1 peptide.The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food.(In Vitro):The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food. GLP-1 exerts multiple actions by stimulating insulin secretion from pancreatic β-cells, in a glucose dependent manner (insulinotropic action). GLP-1 lowers circulating plasma glucagon concentration, by inhibiting its secretion (production) from α-cells. GLP-1 also exhibits properties like stimulation of β-cell growth, appetite suppression, delays gastric emptying and stimulation of insulin sensitivity. The peptide analogs of GLP-1 are useful as glucagon-like peptide 1 receptor agonists.
  • In Vitro
    The GLP-1 (7-36) amide is a product of the preproglucagon gene, which is secreted from intestinal L-cells, in response to the ingestion of food. GLP-1 exerts multiple actions by stimulating insulin secretion from pancreatic β-cells, in a glucose dependent manner (insulinotropic action). GLP-1 lowers circulating plasma glucagon concentration, by inhibiting its secretion (production) from α-cells. GLP-1 also exhibits properties like stimulation of β-cell growth, appetite suppression, delays gastric emptying and stimulation of insulin sensitivity. The peptide analogs of GLP-1 are useful as glucagon-like peptide 1 receptor agonists.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Glucagon Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    926018-45-3
  • Formula Weight
    963.94
  • Molecular Formula
    C40H57N11O17
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

US20120264685
molnova catalog
related products
  • MK-3577

    A potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM.

  • GLP-1(7-37)

    GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells.

  • Orforglipron

    Orforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults.